Ablatus Therapeutics was founded to bring to market Bimodal Electric Tissue Ablation (BETA), an innovative improvement over existing tissue ablation techniques, in order to offer greater clinical options and to improve patient outcomes.
Ablatus was founded in October 2015 and was the first spin-out from the Norfolk and Norwich University Hospital, where the BETA technology was invented. BETA is a form of tissue ablation – a minimally-invasive procedure whereby abnormal tissues (such as tumours) can be destroyed in situ, as an alternative to surgery.
Radiofrequency Ablation (RFA) is an established technique for the treatment of solid tumours in situ. RFA uses Alternating Current to generate radiofrequency (RF) energy, which when delivered to target tissues via a probe, results in localised heating and tissue destruction. RFA has limitations in terms of the size of tumours it can address, but BETA has the potential to improve upon these, potentially allowing the ablation of previously untreatable tumours.
Ablatus was recently awarded £1.4m by the UK government’s Innovate UK to develop its next-generation, minimally-invasive treatment for soft tissue tumours. The award will fund a 2-year project to develop the prototype device into a final version for use in patients for the first time.
Partnering with Cambridge-based product engineering and design specialists eg technology, and Addenbrooke’s Hospital, the grant will enable Ablatus to push forward with gathering essential clinical data needed for CE mark, commercial launch and ultimately to reach patients.
To find out more please visit the company website : https://ablatus.co.uk/.
Natalie Hayes, Interim Chief Executive & Medical Director
Bill Allan, Chairman
Norfolk and Norwich University Hospitals NHS Foundation Trust